Trials / Completed
CompletedNCT05765617
Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Universitas Sebelas Maret · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This research is a study that compares the administration of calcitriol with the outcomes of COVID-19 patients
Detailed description
This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into two groups. The control group received standard therapy, while the treatment group received calcitriol 2x400 iu per day.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Calcitriol | The treatment group received calcitriol 2x400 iu per day for five days. Calcitriol uses Oscal, obtained from Kalbe Pharma |
| OTHER | Placebo | Placebo give 2x1 per day for five day |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2021-09-30
- Completion
- 2021-09-30
- First posted
- 2023-03-13
- Last updated
- 2023-03-13
Locations
1 site across 1 country: Indonesia
Source: ClinicalTrials.gov record NCT05765617. Inclusion in this directory is not an endorsement.